Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347952 | 0.79 | KDM4E (0.55) | EPHX2KDM4ETSHRMAPK14POLB | |
| SCHEMBL21325261 | 0.79 | KDM4E (0.50) | KDM4EPOLB | |
| SCHEMBL20207512 | 0.75 | CNR2 (0.38) | TSHRCNR2 | |
| SCHEMBL22751234 | 0.71 | KDM4E (0.41) | KDM4ECNR2 | |
| SCHEMBL22548331 | 0.70 | HTR2C (0.36) | — | |
| SCHEMBL20351583 | 0.69 | SCN9A (0.34) | — | |
| SCHEMBL20204603 | 0.69 | KDM4E (0.71) | KDM4E | |
| SCHEMBL21325101 | 0.69 | GRM2 (0.44) | CNR2 | |
| SCHEMBL14200213 | 0.68 | KDM4E (0.56) | KDM4ETSHRMAPK14FGFR2POLB | |
| SCHEMBL18376336 | 0.67 | POLB (0.63) | EPHX2KDM4ETSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | EPHX2 470/4885KDM4E 1424/4885TSHR 4661/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | EPHX2 470/4885KDM4E 1424/4885TSHR 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.